Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS)

Takahiro Kuwashiro, Tetsuro Ago, Masahiro Kamouchi, ryu matsuo, Jun Hata, Junya Kuroda, Kenji Fukuda, Hiroshi Sugimori, Masayo Fukuhara, Hideto Awano, Tetsu Isomura, Kazuo Suzuki, Masahiro Yasaka, Yasushi Okada, Yutaka Kiyohara, Takanari Kitazono

研究成果: ジャーナルへの寄稿記事

28 引用 (Scopus)

抄録

Objective Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. We investigated the clinical significance of plasma adiponectin for the diagnosis, neurological severity and functional outcomes of patients with ischemic stroke. Methods We prospectively enrolled 171 patients with ischemic stroke and 171 age- and sex-matched healthy controls. Blood samples and clinical information were obtained at day 0, 3, 7, 14 and 90 after stroke onset. Results Average adiponectin values at day 0 did not significantly differ between the controls and the patients, but were significantly lower and higher in patients with atherothrombotic brain (ATBI) (p = 0.047) and cardioembolic (CE) (p = 0.008) infarction, respectively, than in the controls. Multivariate logistic regression analyses showed that the adiponectin value at day 0 could predict ATBI (odds ratio, 0.75; 95% confidence interval, 0.58 to 0.91, p = 0.009, per 1-μg/mL increase). Adiponectin values at day 0 were positively associated with neurological severity as evaluated by the National Institute of Health Stroke Scale upon admission (r = 0.420, p = 0.003) and were higher in the groups with poor outcomes (modified Rankin Scale (mRS) ≥ 3 on day 90) than in those with good ones (mRS ≤ 2) in all stroke subtypes, with statistical significance in ATBI (p = 0.015). Conclusions Plasma adiponectin values may help to classify stroke subtypes and predict neurological severity and functional outcome in ischemic stroke patients.

元の言語英語
ページ(範囲)1093-1103
ページ数11
ジャーナルMetabolism: Clinical and Experimental
63
発行部数9
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Adiponectin
Biomarkers
Stroke
Research
Brain
Adipokines
National Institutes of Health (U.S.)
Infarction
Cardiovascular Diseases
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

これを引用

Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS). / Kuwashiro, Takahiro; Ago, Tetsuro; Kamouchi, Masahiro; matsuo, ryu; Hata, Jun; Kuroda, Junya; Fukuda, Kenji; Sugimori, Hiroshi; Fukuhara, Masayo; Awano, Hideto; Isomura, Tetsu; Suzuki, Kazuo; Yasaka, Masahiro; Okada, Yasushi; Kiyohara, Yutaka; Kitazono, Takanari.

:: Metabolism: Clinical and Experimental, 巻 63, 番号 9, 01.01.2014, p. 1093-1103.

研究成果: ジャーナルへの寄稿記事

Kuwashiro, Takahiro ; Ago, Tetsuro ; Kamouchi, Masahiro ; matsuo, ryu ; Hata, Jun ; Kuroda, Junya ; Fukuda, Kenji ; Sugimori, Hiroshi ; Fukuhara, Masayo ; Awano, Hideto ; Isomura, Tetsu ; Suzuki, Kazuo ; Yasaka, Masahiro ; Okada, Yasushi ; Kiyohara, Yutaka ; Kitazono, Takanari. / Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS). :: Metabolism: Clinical and Experimental. 2014 ; 巻 63, 番号 9. pp. 1093-1103.
@article{64157497061747a9b9dce22aeab1d7ad,
title = "Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS)",
abstract = "Objective Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. We investigated the clinical significance of plasma adiponectin for the diagnosis, neurological severity and functional outcomes of patients with ischemic stroke. Methods We prospectively enrolled 171 patients with ischemic stroke and 171 age- and sex-matched healthy controls. Blood samples and clinical information were obtained at day 0, 3, 7, 14 and 90 after stroke onset. Results Average adiponectin values at day 0 did not significantly differ between the controls and the patients, but were significantly lower and higher in patients with atherothrombotic brain (ATBI) (p = 0.047) and cardioembolic (CE) (p = 0.008) infarction, respectively, than in the controls. Multivariate logistic regression analyses showed that the adiponectin value at day 0 could predict ATBI (odds ratio, 0.75; 95{\%} confidence interval, 0.58 to 0.91, p = 0.009, per 1-μg/mL increase). Adiponectin values at day 0 were positively associated with neurological severity as evaluated by the National Institute of Health Stroke Scale upon admission (r = 0.420, p = 0.003) and were higher in the groups with poor outcomes (modified Rankin Scale (mRS) ≥ 3 on day 90) than in those with good ones (mRS ≤ 2) in all stroke subtypes, with statistical significance in ATBI (p = 0.015). Conclusions Plasma adiponectin values may help to classify stroke subtypes and predict neurological severity and functional outcome in ischemic stroke patients.",
author = "Takahiro Kuwashiro and Tetsuro Ago and Masahiro Kamouchi and ryu matsuo and Jun Hata and Junya Kuroda and Kenji Fukuda and Hiroshi Sugimori and Masayo Fukuhara and Hideto Awano and Tetsu Isomura and Kazuo Suzuki and Masahiro Yasaka and Yasushi Okada and Yutaka Kiyohara and Takanari Kitazono",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.metabol.2014.04.012",
language = "English",
volume = "63",
pages = "1093--1103",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS)

AU - Kuwashiro, Takahiro

AU - Ago, Tetsuro

AU - Kamouchi, Masahiro

AU - matsuo, ryu

AU - Hata, Jun

AU - Kuroda, Junya

AU - Fukuda, Kenji

AU - Sugimori, Hiroshi

AU - Fukuhara, Masayo

AU - Awano, Hideto

AU - Isomura, Tetsu

AU - Suzuki, Kazuo

AU - Yasaka, Masahiro

AU - Okada, Yasushi

AU - Kiyohara, Yutaka

AU - Kitazono, Takanari

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. We investigated the clinical significance of plasma adiponectin for the diagnosis, neurological severity and functional outcomes of patients with ischemic stroke. Methods We prospectively enrolled 171 patients with ischemic stroke and 171 age- and sex-matched healthy controls. Blood samples and clinical information were obtained at day 0, 3, 7, 14 and 90 after stroke onset. Results Average adiponectin values at day 0 did not significantly differ between the controls and the patients, but were significantly lower and higher in patients with atherothrombotic brain (ATBI) (p = 0.047) and cardioembolic (CE) (p = 0.008) infarction, respectively, than in the controls. Multivariate logistic regression analyses showed that the adiponectin value at day 0 could predict ATBI (odds ratio, 0.75; 95% confidence interval, 0.58 to 0.91, p = 0.009, per 1-μg/mL increase). Adiponectin values at day 0 were positively associated with neurological severity as evaluated by the National Institute of Health Stroke Scale upon admission (r = 0.420, p = 0.003) and were higher in the groups with poor outcomes (modified Rankin Scale (mRS) ≥ 3 on day 90) than in those with good ones (mRS ≤ 2) in all stroke subtypes, with statistical significance in ATBI (p = 0.015). Conclusions Plasma adiponectin values may help to classify stroke subtypes and predict neurological severity and functional outcome in ischemic stroke patients.

AB - Objective Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. We investigated the clinical significance of plasma adiponectin for the diagnosis, neurological severity and functional outcomes of patients with ischemic stroke. Methods We prospectively enrolled 171 patients with ischemic stroke and 171 age- and sex-matched healthy controls. Blood samples and clinical information were obtained at day 0, 3, 7, 14 and 90 after stroke onset. Results Average adiponectin values at day 0 did not significantly differ between the controls and the patients, but were significantly lower and higher in patients with atherothrombotic brain (ATBI) (p = 0.047) and cardioembolic (CE) (p = 0.008) infarction, respectively, than in the controls. Multivariate logistic regression analyses showed that the adiponectin value at day 0 could predict ATBI (odds ratio, 0.75; 95% confidence interval, 0.58 to 0.91, p = 0.009, per 1-μg/mL increase). Adiponectin values at day 0 were positively associated with neurological severity as evaluated by the National Institute of Health Stroke Scale upon admission (r = 0.420, p = 0.003) and were higher in the groups with poor outcomes (modified Rankin Scale (mRS) ≥ 3 on day 90) than in those with good ones (mRS ≤ 2) in all stroke subtypes, with statistical significance in ATBI (p = 0.015). Conclusions Plasma adiponectin values may help to classify stroke subtypes and predict neurological severity and functional outcome in ischemic stroke patients.

UR - http://www.scopus.com/inward/record.url?scp=84906222971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906222971&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2014.04.012

DO - 10.1016/j.metabol.2014.04.012

M3 - Article

C2 - 24929894

AN - SCOPUS:84906222971

VL - 63

SP - 1093

EP - 1103

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -